According to Regeneron Pharmaceuticals's latest financial reports and stock price the company's current Operating Margin is 39.91%. At the end of 2021 the company had an Operating Margin of 58.03%.
Year | Operating Margin | Change |
---|---|---|
2021 | 58.03% | 29.4% |
2020 | 44.84% | 45.17% |
2019 | 30.89% | -18.82% |
2018 | 38.05% | 7.5% |
2017 | 35.40% | 29.37% |
2016 | 27.36% | -8.35% |
2015 | 29.85% | 8.51% |
2014 | 27.51% | -18.82% |
2013 | 33.89% | 12.74% |
2012 | 30.06% | -160.13% |
2011 | -50.00% | 119.7% |
2010 | -22.76% | 19.95% |
2009 | -18.97% | -43.7% |
2008 | -33.70% | -63.19% |
2007 | -91.55% | -46.05% |
2006 | -169.68% | -190.27% |
2005 | 187.97% | 5693.39% |
2004 | 3.24% | -101.87% |
2003 | -173.90% | -68.65% |
2002 | -554.63% | 42.23% |
2001 | -389.95% |
Company | Operating Margin | Operating Margin differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | 24.28% | -39.16% | ๐บ๐ธ USA |
![]() Novartis NVS | 16.16% | -59.51% | ๐จ๐ญ Switzerland |
![]() Amgen AMGN | 34.79% | -12.83% | ๐บ๐ธ USA |
![]() Sanofi SNY | 19.90% | -50.14% | ๐ซ๐ท France |
![]() Biogen BIIB | 36.44% | -8.69% | ๐บ๐ธ USA |
![]() Alnylam Pharmaceuticals
ALNY | -100.93% | -352.89% | ๐บ๐ธ USA |
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.